Sawai Group Holdings Co., Ltd.

Tokyo Stock Exchange 4887.T

Sawai Group Holdings Co., Ltd. EBITDA Margin for the year ending March 31, 2024: 20.85%

Sawai Group Holdings Co., Ltd. EBITDA Margin is 20.85% for the year ending March 31, 2024, a 23.10% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Sawai Group Holdings Co., Ltd. EBITDA Margin for the year ending March 31, 2023 was 16.94%, a 275.46% change year over year.
  • Sawai Group Holdings Co., Ltd. EBITDA Margin for the year ending March 31, 2022 was -9.65%, a -148.51% change year over year.
  • Sawai Group Holdings Co., Ltd. EBITDA Margin for the year ending March 31, 2021 was 19.90%, a -19.30% change year over year.
  • Sawai Group Holdings Co., Ltd. EBITDA Margin for the year ending March 31, 2020 was 24.66%, a 7.01% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Loading...
SV Wall Street
Tokyo Stock Exchange: 4887.T

Sawai Group Holdings Co., Ltd.

CEO Mr. Mitsuo Sawai
IPO Date April 1, 2021
Location Japan
Headquarters 5-2-30, Miyahara
Employees 3,482
Sector Healthcare
Industries
Description

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.

Similar companies

4521.T

Kaken Pharmaceutical Co., Ltd.

USD 27.19

-2.00%

4553.T

Towa Pharmaceutical Co., Ltd.

USD 19.43

-1.89%

4506.T

Sumitomo Pharma Co., Ltd.

USD 3.93

2.09%

4540.T

Tsumura & Co.

USD 29.51

-0.48%

4516.T

Nippon Shinyaku Co., Ltd.

USD 24.26

-0.77%

StockViz Staff

February 2, 2025

Any question? Send us an email